APMIS is a distinguished academic journal published by WILEY that serves as a vital resource for researchers and practitioners in the fields of Immunology, Allergy, Microbiology, and Pathology. Established in 1988 and continuing its mission through 2024, this journal facilitates the dissemination of high-quality research findings, contributing to the intersection of multiple disciplines within the medical sciences. With an ISSN of 0903-4641 and an E-ISSN of 1600-0463, APMIS is categorized in 2023's Q2 and Q3 quartiles across various domains, reflecting its significant impact, with rankings such as #50/208 in Pathology and Forensic Medicine and #121/233 in Immunology and Allergy. Although it currently does not offer open access options, the journal’s rigorous peer-review process ensures that published articles maintain the highest standards of scholarship. With its focus on innovative research, APMIS continues to occupy a pivotal role for those seeking to advance their expertise and contribute to scientific dialogue in these essential fields.

Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

Journal of Immunology Research, published by HINDAWI LTD, stands as a pivotal open-access journal in the realm of immunology, with a particular emphasis on advancing knowledge in both fundamental and applied aspects of the field. Since its inception in 1990, the journal has committed to the dissemination of high-quality research, earning a respectable impact factor that reflects its significance. Based in Egypt, it provides a platform for researchers from around the world, showcasing innovative studies and reviews that contribute to the understanding of immune system mechanisms. Its 2023 rankings place it in the Q2 category for Immunology and Allergy, and Q1 in the broader category of Medicine (miscellaneous), indicating a strong reputation among its peers. Through its open-access model, the journal promotes wide accessibility of cutting-edge research, catering to researchers, professionals, and students alike. With ambitions that converge through 2024, the Journal of Immunology Research continues to be an essential resource for those seeking to explore the forefront of immunological science.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

ANNALS OF CLINICAL AND LABORATORY SCIENCE, published by the Association of Clinical Scientists, is a pivotal journal in the fields of clinical biochemistry, hematology, immunology, and medical laboratory technology. Since its inception in 1971, this journal has become a vital resource for researchers and practitioners aiming to advance their knowledge and skills in laboratory sciences. Although currently not an open access journal, its rich repository of peer-reviewed articles and studies contributes significantly to the academic discourse in diagnostic and therapeutic practices. The journal is categorized in various quartiles, reflecting its impact and contributions to multiple scientific domains, such as Q4 in Clinical Biochemistry and Q3 in Pathology and Forensic Medicine as of 2023. With an extensive convergence of years up to 2024, it proves to be a timeless source for emerging trends and research innovations. The ANNALS OF CLINICAL AND LABORATORY SCIENCE not only supports the professional development of its readers but also encourages interdisciplinary collaboration, making it an essential tool for professionals, students, and researchers dedicated to improving health outcomes through advanced laboratory sciences.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

Autoimmune Diseases is a leading open-access journal published by Hindawi Ltd, dedicated to advancing the understanding and treatment of autoimmune disorders. Since its inception in 2010, this journal has provided a vital platform for researchers, clinicians, and students to share innovative findings and insights from the field of immunology. With an impressive Scopus ranking that highlights its relevance, particularly in the areas of Immunology and Microbiology and Immunology and Allergy, Autoimmune Diseases occupies a key position in the scientific discourse, ranking in the top quartiles across various categories. Researchers publishing in this journal benefit from a wide audience and high visibility, reflecting the increasing importance of understanding autoimmune diseases in today’s health landscape. Accessible to all, the journal promotes collaborative research and discussion, making it an essential resource for anyone dedicated to the study and management of autoimmune conditions.

Veterinary Immunology and Immunopathology is a premier journal published by Elsevier, dedicated to advancing the field of veterinary science through rigorous investigations into the immunological mechanisms that underpin disease resistance, pathogenesis, and therapeutic interventions in animals. With an established history since 1979, this journal has consistently provided a platform for high-quality research, bridging the gap between immunology and veterinary medicine. The current impact factor reflects its significance within the field, particularly noted for its Q3 ranking in Immunology and Q2 in miscellaneous Veterinary categories as of 2023. The journal caters to a diverse audience, from seasoned researchers to students, by publishing original research, reviews, and case studies that explore pivotal topics such as vaccine development, immune response in various species, and the role of genetics in immunological disorders. Notably, it is indexed in Scopus, where it ranks in the top percentile of veterinary science disciplines, enhancing its visibility and impact within the scientific community. For those seeking to stay at the forefront of veterinary immunology, this journal is an invaluable resource.